Akebia Therapeutics (AKBA) PT Raised to $21 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Pre-Open Movers 05/16: (AKBA) (ETSY) (SINA) Higher; (PTX) (DKS) (SSYS) Lower (more...)
May 16, 2017 9:24 AM EDTToday's Pre-Open Movers
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) 25% LOWER; First quarter 2017 net revenues decreased 8.6% from the first quarter of 2016, to $29.7 million from $32.5 million. Amended Wells Fargo credit facility. Company intends to transition to another financing source on or before July 31, 2017.
xG Technology, Inc. (Nasdaq: XGTI) 17.9% HIGHER; reports Q1 results
S&P 500, Dow end session flat, tech boosts Nasdaq
May 16, 2017 7:26 AM EDTBy Sinead Carew
NEW YORK (Reuters) - The S&P 500 and the Dow ended Tuesday's session flat after mixed economic data and retail earnings, while the Nasdaq had another record close with help from technology stocks.
U.S. manufacturing production showed its biggest increase in more than three years in April, bolstering a view that economic growth picked up early in the second quarter despite a surprise decline in homebuilding.
Investors were also cautious about potential delays to the government's tax and regulation reform agenda after reports late Monday that President Donald Trump disclosed highly classified... More
Akebia Therapeutics (AKBA): Raising PT On Key Contract - HC Wainwright
May 16, 2017 7:26 AM EDTH.C. Wainwright analyst, Ed Arce, reiterated his Neutral rating on shares of Akebia Therapeutics (NASDAQ: AKBA) and raised his price target to $25 after the company announced a partnership with Vifor Pharma to provide vadadustat to Fresenius Medical Care as its exclusive HIFbased
therapy... More
Akebia Therapeutics (AKBA) Secures $50M Investment at $14/Sh from Vifor Pharma for Exclusive Distribution of Vadadustat to Fresenius Medical Care North America for Dialysis Facilities
May 16, 2017 5:53 AM EDTAkebia Therapeutics, Inc. (NASDAQ: AKBA) and Vifor Pharma Group today announced they have entered into an exclusive license agreement to sell vadadustat to Fresenius Medical Care dialysis clinics in the United States upon approval by the U.S. Food and Drug Administration... More
After-Hours Stock Movers 05/15: (AKBA) (ETSY) (BDSI) Higher; (PTX) (TEAR) (PRKR) Lower (more...)
May 15, 2017 6:28 PM EDTToday's After-Hours Movers
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) 25% LOWER; First quarter 2017 net revenues decreased 8.6% from the first quarter of 2016, to $29.7 million from $32.5 million. Amended Wells Fargo credit facility. Company intends to transition to another financing source on or before July 31, 2017.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) 14.7% HIGHER; The company and Vifor Pharma Group. today announced they have entered into an exclusive license agreement to sell vadadustat to Fresenius Medical Care... More
Akebia Therapeutics (AKBA), Vifor Pharma Enter Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care; Deal Includes $50M Equity Investment
May 15, 2017 4:06 PM EDTAkebia Therapeutics, Inc. (NASDAQ: AKBA) and Vifor Pharma Group. today... More
